Showing results (41-50 of 50) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Clinical Immunology (Orlando, Fla.)|October 20, 2024
Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cellsFrancesca Ammoscato, Mohammad Wafa, Justyna Skonieczna, et al.Journal of Neuroimmunology|October 25, 2003
A whole genome association study in multiple sclerosis patients from north PortugalBerta Martins Silva, Theodora Thorlacius, Kjartan Benediktsson, et al.Multiple Sclerosis and Related Disorders|November 13, 2018
Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policiesZhifeng Mao, César Álvarez-González, Kimberley Allen-Philbey, et al.AIDS (London, England)|June 15, 2021
The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-seriesTerrence Y-H Chan, Valentina De Zan, Alistair Gregg, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 22, 2004
T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosisMohsen Khademi, Zsolt Illés, Alexander W Gielen, et al.BMJ Open|November 26, 2021
OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosisRuth Dobson, Matthew Craner, Ed Waddingham, et al.Brain : a Journal of Neurology|October 8, 2021
The impact of smoking cessation on multiple sclerosis disease progressionJeff Rodgers, Tim Friede, Frederick W Vonberg, et al.Multiple Sclerosis and Related Disorders|May 31, 2022
Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS)Ruth Dobson, Matthew Craner, Ed Waddingham, et al.Therapeutic Advances in Neurological Disorders|July 14, 2020
Sex effects across the lifespan in women with multiple sclerosisKristen M Krysko, Jennifer S Graves, Ruth Dobson, et al.Therapeutic Advances in Neurological Disorders|February 17, 2022
Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patientsKimberley Allen-Philbey, Stefania De Trane, Zhifeng Mao, et al.Pageof 5